1Center for Cancer Education and Information, Seoul National University Hospital, Seoul, Korea.
2College of Nursing, Seoul National University, The Research Institute of Nursing Science, Seoul, Korea.
© 2012 Korean Society of Nursing Science
This article is an addition based on the first author's master's thesis from Seoul National University.
Exp.=Experimental group; Cont.=Control group; FOLFOX=Oxaliplantin+Leucovorin+5-Fluorouracil; FOLFIRI=Irinotecan+Leucovorin+5-Fluorouracil.
Exp.=Experimental group; Cont.=Control group; DRICP (%)=Dietary reference intakes for cancer patient.
Exp.=Experimental group; Cont.=Control group; FDOTE=Fat distribution of total energy.
Exp.=Experimental group; Cont.=Control group; FOLFOX=Oxaliplantin+Leucovorin+5-Fluorouracil; FOLFIRI=Irinotecan+Leucovorin+5-Fluorouracil.
Exp.=Experimental group; Cont.=Control group; DRICP (%)=Dietary reference intakes for cancer patient.
Exp.=Experimental group; Cont.=Control group; FDOTE=Fat distribution of total energy.